Pharmacotoxicology of monocyte-macrophage nanoformulated antiretroviral drug uptake and carriage

Nanotoxicology

Volumn 5, Issue 4, 2011, Pages 592-605

  Bressani, Rafael F ^a   Nowacek, Ari S ^a   Singh, Sangya ^a   Balkundi, Shantanu ^a   Rabinow, Barrett ^b   McMillan, Joellyn ^a   Gendelman, Howard E ^a   Kanmogne, Georgette D ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Antiretroviral therapy; Blood brain barrier; Monocytes and macrophages; NanoART; Nanomedicine; Nanotoxicity; Pharmacotoxicology

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; FLUCONAZOLE; INDINAVIR; NANOPARTICLE; OCCLUDIN; PROTEIN ZO2; RITONAVIR; SURFACTANT; TUMOR NECROSIS FACTOR ALPHA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG FORMULATION; DRUG TRANSPORT; DRUG UPTAKE; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; MACROPHAGE; MONOCYTE; NANOMEDICINE; NANOPHARMACEUTICS; PARTICLE SIZE; PRIORITY JOURNAL; TIGHT JUNCTION;

ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; BLOOD-BRAIN BARRIER; CELL SURVIVAL; CELLS, CULTURED; ENDOTHELIAL CELLS; HUMANS; MACROPHAGES; MEMBRANE PROTEINS; MONOCYTES; NANOCAPSULES;

EID: 80655144950     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2010.541292     Document Type: Article

References (37)

1. Bartlett JA., Shao JF. 2009. Successes, challenges, and limitations of current antiretroviral therapy in low-income and middle-income countries. Lancet Infect Dis 9:637-649.
2. Beauliere A, Le Maux A, Trehin C, Perez F. 2010. Access to antiretroviral treatment in developing countries: Which financing strategies are possible? Rev Epidemiol Sante Publique 58:171-179.
3. Beduneau A, Ma Z, Grotepas CB, Kabanov A, Rabinow BE, Gong N, Mosley RL, Dou H, Boska MD, Gendelman HE. 2009. Facilitated monocyte-macrophage uptake and tissue distribution of superparmagnetic iron-oxide nanoparticles. PLoS One 4:e4343.
4. Berg CJ, Michelson SE, Safren SA. 2007. Behavioral aspects of HIV care: Adherence, depression, substance use, and HIV-transmission behaviors. Infect Dis Clin North Am 21:181-200. (Pubitemid 46729632)
5. Blas-Garcia A, Apostolova N, Ballesteros D, Monleon D, Morales JM, Rocha M, Victor VM, Esplugues JV. 2010. Inhibition of mitochondrial function by efavirenz increases lipid content in hepatic cells. Hepatology 52:115-125.
6. Chattopadhyay N, Zastre J, Wong HL, Wu XY, Bendayan R. 2008. Solid lipid nanoparticles enhance the delivery of the HIV protease inhibitor, atazanavir, by a human brain endothelial cell line. Pharm Res 25:2262-2271.
7. Chaudhuri A, Yang B, Gendelman HE, Persidsky Y, Kanmogne GD. 2008. STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier. Blood 111:2062-2072. (Pubitemid 351451518)
8. Chen L, Yokel RA, Hennig B, Toborek M. 2008. Manufactured aluminum oxide nanoparticles decrease expression of tight junction proteins in brain vasculature. J Neuroimmune Pharmacol 3:286-295.
9. Conway B. 2007. The role of adherence to antiretroviral therapy in the management ofHIV infection. J Acquir Immune Defic Syndr 45(Suppl. 1):S14-18. (Pubitemid 46828215)
10. Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, Martinez-Picado J. 2008. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 13:945-951.
11. Debbage P. 2009. Targeted drugs and nanomedicine: Present and future. Curr Pharm Des 15:153-172.
12. Dou H, Destache CJ, Morehead JR, Mosley RL, Boska MD, Kingsley J, Gorantla S, Poluektova L, Nelson JA, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. 2006. Development of a macrophage-based nanoparticle platform for anti-retroviral drug delivery. Blood 108:2827-2835.
13. Dou H, Grotepas CB, McMillan JM, Destache CJ, Chaubal M, Werling J, Kipp J, Rabinow B, Gendelman HE. 2009. Macro-phage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 183:661-669.
14. Dou H, Morehead J, Destache CJ, Kingsley JD, Shlyakhtenko L, Zhou Y, Chaubal M, Werling J, Kipp J, Rabinow BE, Gendelman HE. 2007. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macro-phages. Virology 358:148-158. (Pubitemid 46048870)
15. Dougherty GM, Rose KA, Tok JB, Pannu SS, Chuang FY, Sha MY, Chakarova G, Penn SG. 2008. The zeta potential of surface-functionalized metallic nanorod particles in aqueous solution. Electrophoresis 29:1131-1139. (Pubitemid 351404688)
16. Gendelman HE, Kabanov A, Linder J. 2008. The promise and perils of CNS drug delivery: A video debate. J Neuroimmune Pharmacol 3:58.
17. Gendelman HE, Orenstein JM, Martin MA, Ferrua C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, Burke DS, et al. 1988. Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated mono-cytes. J Exp Med 167:1428-1441.
18. Ghosh S, Mashayekhi H, Pan B, Bhowmik P, Xing B. 2008. Colloidal behavior of aluminum oxide nanoparticles as affected by pH and natural organic matter. Langmuir 24:12385-12391.
19. Gorantla S, Dou H, Boska M, Destache CJ, Nelson J, Poluektova L, Rabinow BE, Gendelman HE, Mosley RL. 2006. Quantitative magnetic resonance and SPECT imaging for macrophage tissue migration and nanoformulated drug delivery. J Leukoc Biol 80:1165-1174. (Pubitemid 44646322)
20. Kanmogne GD, Primeaux C, Grammas P. 2005. HIV-1 gp120 proteinsaltertightjunctionproteinexpressionandbrain endothelial cell permeability: Implications for the pathogenesis of HIV-associated dementia. J Neuropathol Exp Neurol 64:498-505. (Pubitemid 40781152)
21. Kanmogne GD, Schall K, Leibhart J, Knipe B, Gendelman HE, Persidsky Y. 2007. HIV-1 gp120 compromises blood-brain barrier integrity and enhances monocyte migration across blood-brain barrier: Implication for viral neuropathogenesis. J Cereb Blood Flow Metab 27:123-134. (Pubitemid 46006590)
22. Khemtong C, Kessinger CW, Gao J. 2009. Polymeric nanomedi-cine for cancer MR imaging and drug delivery. Chem Commun (Camb):3497-3510.
23. Kiertiburanakul S, Sungkanuparph S. 2009. Emerging of HIV drug resistance: Epidemiology, diagnosis, treatment and prevention. Curr HIV Res 7:273-278.
24. Kim JY, Ammann A. 2004. Is the '3 by 5' initiative the best approach to tackling the HIV pandemic? PLoS Med 1:e37.
25. Kuo YC, Su FL. 2007. Transport of stavudine, delavirdine, and saquinavir across the blood-brain barrier by polybutylcyanoa-crylate, methylmethacrylate- sulfopropylmethacrylate, and solid lipid nanoparticles. Int J Pharm 340:143-152.
26. Moreno S, Lopez Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F. 2010. The future of antiretroviral therapy: Challenges and needs. J Antimicrob Chemother 65:827-835.
27. Muthu MS, Singh S. 2009. Targeted nanomedicines: Effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine 4:105-118.
28. Nowacek A, Gendelman HE. 2009. NanoART, neuroAIDS and CNS drug delivery. Nanomedicine (Lond) 4:557-574.
29. Nowacek A, Kosloski LM, Gendelman HE. 2009a. Neurodegen-erative disorders and nanoformulated drug development. Nanomedicine (Lond) 4:541-555.
30. Nowacek AS, Miller RL, McMillan J, Kanmogne G, Kanmogne M, Mosley RL, Ma Z, Graham S, ChaubalM, Werling J, Rabinow B, Dou H, Gendelman HE. 2009b. NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery. Nanomedicine (Lond) 4:903-917.
31. Rebiere H, Mazel B, Civade C, Bonnet PA. 2007. Determination of 19 antiretroviral agents in pharmaceuticals or suspected products with two methods using high-performance liquid chroma-tography. J Chromatogr B Analyt Technol Biomed Life Sci 850:376-383. (Pubitemid 46618184)
32. Sandelowski M, Voils CI, Chang Y, Lee EJ. 2009. A systematic review comparing antiretroviral adherence descriptive and intervention studies conducted in the USA. AIDS Care 21:953-966.
33. SlowingI,TrewynBG,LinVS.2006.Effectofsurfacefunctionalization of MCM-41-type mesoporous silica nanoparticles on the endocy-tosis by human cancer cells. J Am Chem Soc 128:14792-14793.
34. UNAIDS. 2009. AIDS epidemic update. UNAIDS/09.36E/JC1700E.
35. Vallhov H, Gabrielsson S, Stromme M, Scheynius A, Garcia-Bennett AE. 2007. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett 7:3576-3582.
36. Waters L, Nelson M. 2007. Why do patients fail HIV therapy? Int J Clin Pract 61:983-990. (Pubitemid 46744073)
37. Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. 2007. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 848:369-373. (Pubitemid 46453288)